President Trump's executive order on marijuana's classification could bring changes to Oklahoma

President Trump signed an executive order initiating the rescheduling of marijuana from Schedule I to Schedule III and instructed Attorney General Pam Bondi to take steps to effect the change, a process expected to take much of 2026. The move could materially reduce compliance and banking frictions for cannabis businesses—enabling payroll, accounting and research access—while leaving state regulatory regimes, including Oklahoma's moratorium on new licenses through Aug. 1, 2026, intact and likely supporting stable local prices. Market implications are sector-specific: positive for incumbent cannabis operators and service providers (banks, payroll/accounting vendors, research firms) but conditional on a multi-step federal process and state-level rules.

Analysis

Market structure: Rescheduling from Schedule I to III is a slow but meaningful de-risking event for vertically integrated US MSOs, payment processors and cannabis REITs — expect 300–800 bps potential EBITDA margin improvement and a 20–60% equity re-rating for compliant MSOs if banks and tax treatment follow within 12–24 months. Winners: large, cash-flowing operators with compliant track records (scale, auditing, banking-ready). Losers: highly leveraged, expansion-first MSOs and small mom‑and‑pop operators that depend on cash-only models or new-license expansion to grow.

Risk assessment: Immediate (days) — headline volatility and a rotation into cannabis names; short-term (weeks–months) — limited fundamental change until DOJ/DEA rulemaking and FinCEN/Treasury guidance; long-term (12–36+ months) — meaningful credit spread compression and M&A. Tail risks include a DOJ or regulatory reversal, no change to Section 280E tax treatment, or persistent bank refusal to onboard MSOs; any of these would erase >50% of upside in many names.

Trade implications: Favours longer‑dated, concentrated directional bets on large diversified operators and optionality via LEAPS; capital markets and credit should tighten for investment‑grade‑like MSOs once banks re-engage. Cross-asset: expect tightening in high-yield spreads for cannabis credits, limited FX/commodity moves, and elevated equity implied vols — use 9–24 month option structures to express view.

Contrarian angles: The market underestimates how much state-by-state regulation and 280E tax code will blunt immediate benefits — rescheduling ≠ interstate commerce or automatic tax relief. The consensus may be overenthusiastic on short-term winners; a more realistic path is 12–36 months of consolidation where real winners are those that secure banking, licensing and vertical integration.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Tilray Brands (TLRY) to play diversified international + pharma exposure; target 30–60% upside over 12–24 months if banking access and margin recovery materialize, stop-loss 35% from entry.
• Establish a 1–2% long in Trulieve (TRUL / TCNNF) for a state-dominant cash-flow play protected by license moratoria; target 25–50% upside in 12–18 months, reduce position if quarterly cash EBITDA falls >15% sequentially.
• Initiate a 1% short position in Cresco Labs (CRLBF) (or largest pure-play expansion-focused MSO without banking/compliance leadership); thesis: weaker balance sheet and execution risk lead to underperformance during consolidation — cover on a 30–40% rally or positive DOJ/FinCEN guidance.
• Buy TLRY Jan 2027 LEAPS (9–18 month minimum, prefer Jan 2027) equal to 0.5–1% of portfolio as convex upside exposure; if long underlying, hedge by selling 6–9 month covered calls at 20–30% OTM to finance cost.
• Set alerts and tranche sizing tied to hard catalysts: (a) DOJ/DEA proposed rule or scheduling notice — scale in 50% of planned allocation on publication; (b) Treasury/FinCEN bank guidance enabling correspondent banking — add remaining 50% within 30 trading days of final guidance; if neither occurs by Dec 31, 2026, reduce exposure by 50%.